Obiectiv: aprecierea eficacitatii clorquinaldol-promestriene in tratamentul vaginitelor.

Material si metoda. Studiul a fost realizat pe un lot de 20 de femei care s-au adresat pentru leucoree Laboratorului de Bacteriologie al Centrului Dermato-venerologic Bucuresti. Diagnosticul a fost stabilit prin examen direct pe frotiu, nu au fost incluse in studiu bolnavele cu gonoree. Toate bolnavele au fost testate serologic pentru sifilis si infectia HIV. Bolnavelor li s-au administrat cate 2 comprimate vaginale de clorquinaldol-promestriene pe zi, timp de 9 zile; in cazul persistentei simptomatologiei tratamentul a fost prelungit cu inca 9 zile. S-au urmarit: intensitatea leucoreei, aspectul colului uterin, al vaginului si al vulvei si dinamica simptomatologiei asociate. Controalele clinic si bacteriologic au fost efectuate inainte de inceperea tratamentului, a treia si a saptea zi de la terminarea tratamentului.

Rezultate. Varsta medie a bolnavelor a fost de 32,6 ani. Examenul bacteriologic a evidentiat T. vaginalis in 8 cazuri, C. albicans in 3 cazuri, Gardnerella vaginalis in 3 cazuri si flora nespecifica in 6 cazuri. Simptomatologia, leucoreea si semnele inflamatorii s-au remis dupa prima cura de tratament in 16 cazuri (80%) si dupa a doua cura in restul cazurilor. Controlul bacteriologic postterapeutic a fost negativ in toate cazurile. Nu au fost semnalate reactii adverse.

Concluzii. Prin componentele sale, clorchinaldolul (derivat de chinoleina cu activitate antiseptica) si promestriena (activitatea trofica asupra mucoasei vaginale), Colposeptine® reprezinta o alternativa eficienta in tratamentul vaginitelor.

Objective: to determine the efficacy of chlorquinaldol-promestriene in the therapy of vaginitis.

Methods. The study was performed among 20 women who attended the Dermato-venereological Center Bucharest for leukorrhea. The etiologic diagnosis was made by direct examen on Gram-stained smear; patients with gonorrhea were not included in study. All patients were tested for syphilis and HIV infection. The patients were received chlorquinalddol-promestriene, 2 vaginal tablets daily for 9 days.

In case of persistent symptoms the therapy was prolonged for another 9 days, 2 tablets daily. The standardized follow-up concerned the degree of leukorrhea, the condition of cervix, vagina and vulva and subjective signs. Clinical and bacteriologic controls were made before beginning of therapy and at 1, 3 and 7 days after last day of treatment.

Results. The mean age of patients was 32,6 years. The bacteriologic exam evidentiated T. vaginalis in 8 cases, C. albicans, in 3 cases, Gardnerella vaginalis in 3 cases and nonspecific flora in 6 cases. Subjective signs, leukorrhea, and inflammatory signs disappeared after 9 days of treatment in 16 cases (80%) and after prolonged treatment in 4 cases. Posttherapeutical bacteriologic controls were negative in all cases. No side effects were registered.

Conclusions. By its active principles, chlorquinaldol (a contact antiseptic, derivative of quinolein) and promestriene (trophic action on vaginal mucosa), Colposeptine® is an efficient alternative for therapy of vaginitis.